736 results about "Gastric cancer cell" patented technology

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with stomach cancer. The biological compositions can be used to retard the growth of stomach cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention discloses a targeted artificial TS / MDEP protein nucleic acid aptamer and a sequence thereof. A new combinatorial chemistry technology SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is applied, the TS / MDEP protein serves as a target protein, and a DNA aptamer capable of being in specific binding to the TS / MDEP protein is screened from a single-chain RNA random library. The aptamer can form a special stem-loop structure in a random sequence area and can be in specific and high-affinity binding to the TS / MDEP protein or targeted binding to gastric cancer cells. The RNA aptamer provides a specific and efficient marker molecule for the gastric cancer diagnosis and treatment field, as well as a new choice for developing gastric cancer diagnosis reagents and gastric cancer treatment medicines.

The invention relates to quercetin-3-O-acyl ester and a preparation method thereof and belongs to the technical field of pharmaceutical chemistry. The preparation method comprises the following steps: taking cheap rutin as a starting raw material and preparing a quercetin-3-O-acyl ester compound through benzylation, hydrolysis under the acidic conditions, esterification, catalytic hydrogenolysis and other reactions. The method has the characteristics of good selectivity, mild reaction condition, high yield, low cost, simplicity and convenience in operation, easiness in industrial production and the like. In addition, the inhibitory effect of the obtained quercetin-3-O-acyl ester on human esophageal squamous carcinoma cells EC9706, human prostatic cancer cells PC-3 and human gastric cancer cells MGC-803 is remarkably superior to that of quercetin; and the quercetin-3-O-acyl ester can be used in the field of foods and medicines and is possible to develop into a new candidate drug for treating tumor.

A RNA nanoparticle is disclosed. According to base pairing rules, a particle is formed from a chain RNA, b chain RNA and c chain RNA, wherein sequence of the a chain RNA is SEQ ID No.1; sequence of the b chain RNA is SEQ ID No.2; and sequence of the c chain RNA is SEQ ID No.3. It shows through experimental verification at the cellular and animal level that the RNA nanoparticle provided by the invention has good biosecurity and excellent gene interference effect and specificity, can effectively inhibit growth of gastric cancer cell lines and transplant subcutaneous sarcoma and can be applied in prevention, cure and diagnosis of stomach cancer.

The invention discloses a CRISPR-Cas9 system for knocking out the gene GRIN2D and its application. The CRISPR-Cas9 system comprises Cas9 and gRNA specifically targeting to the gene GRIN2D. The invention also discloses application of the CRISPR-Cas9 system to preparation of drugs used for treating cancer and application of the gene GRIN2D to diagnostic kits and medicines used for precise treatmentof stomach cancer and other tumors. In virtue of a clinical sample tissue chip of stomach cancer, the gene GRIN2D is proved to be increased in expression in stomach cancer tissue and be related to prognosis according to immunohistochemical results. The CRISPR-Cas9 system provided by the invention can highly efficiently knock out the highly-expressed gene GRIN2D in stomach cancer and inhibit the proliferation and migration / invasion of gastric cancer cells, and is simple to operate and high in knockout efficiency. The CRISPR-Cas9 system is expected to be applied to diagnosis and treatment of stomach cancer and other tumors with over-expressed GRIN2D. The CRISPR-Cas9 system is applicable to a plurality of tumors with abnormal expression of GRIN2D.

The invention relates to a cyclic RNA molecular marker for diagnosis of gastric cancer, the cyclic RNA molecular marker is characterized in that the cyclic RNA is hsa-circ-0001017, the invention also provides a method for detection of the cyclic RNA molecular marker in plasma, and the method comprises the following steps: (1) collecting blood, and extracting total RNA in the plasma; (2) performing reverse transcription of the total RNA into cDNA; (3) performing droplet digital PCR detection of a cDNA solution of the step (2) by use of specific amplification back-to-back primers and amplification upstream and downstream primers of housekeeping gene GAPDH, after the completion of the reaction, detecting fluorescence signal values of all droplets, setting a threshold, and determining whether the droplets include the cyclic RNA or the housekeeping gene GAPDH, wherein the droplets higher than the threshold are positive droplets, and the droplets below the threshold are negative droplets; and (4) counting the number of the positive droplets, and calculating the copy number of the hsa-circ-0001017 and the housekeeping gene GAPDH in the plasma for quantitative detection of the hsa-circ-0001017 and the housekeeping gene GAPDH in the plasma. Compared with the prior art, the advantages are that the hsa-circ-0001017 can be specifically expressed in plasma in patients with gastric cancer, and can be used as a new molecular marker for diagnosis of the gastric cancer.

The invention relates to application of co-blocking of PD-1 and TIM-3 signal paths to anti-stomach-cancer treatment, and in particular relates to a blocking agent of the PD-1 signal path, a blocking agent of the TIM-3 signal path and application of the blocking agents together with the conventional anti-stomach-cancer treatment medicaments to preparation of a medicinal composition for resisting stomach cancer. The blocking agents or a combination of the blocking agents and the conventional anti-stomach-cancer medicaments treats stomach cancer by enhancing the stomach cancer cell killing effect of T cells. The composition has a remarkable treatment effect, and has the advantages of small toxic and side effects and cooperation with the conventional stomach cancer treatment medicaments.

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol A1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. Experiments prove that the compound has better anti-tumor activity on various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal squamous carcinoma cells KYSE450, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC and human gastric carcinoma cells HGC-27.

The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity of TMPRSS4 serine protease and the suppression of the infiltration of TMPRSS4-expressed cancer cells, and thus can be useful as a composition for preventing or treating cancer by inhibiting TMPRSS4 over-expressed in cancer cells, particularly, colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, or stomach cancer cells.

The invention discloses a Chinese medicinal composition for treating malignant tumor, belonging to the field of Chinese medicines. The Chinese medicinal composition is a medicament preparation formed from herba oldenlandiae, astragalus root, tuckahoe, prepared pinellia tuber, herba scutellariae barbatae, teloon, scorpion, scolopendra and the like by adopting advanced processes including extraction with water, extraction with ethanol, enzymolysis of trypsinase and the like according to a certain compatible requirement, and the medicament preparation is preferably prepared into capsules and tablets. The Chinese medicinal composition has a certain function for relieving symptoms for lung cancer, liver cancer, gastric cancer, intestinal cancer, breast cancer, encephaloma, lymph cancer and other malignant tumors, reducing tumor bodies, inhibiting the growth of the tumors and the like; and according to the Chinese medicinal composition, the human immune capability can be improved, the lives of patients suffered from tumors can be prolonged and the adverse reactions of leukocytopenia, dizzy, weakness and fatigue, skinniness, poor appetite, nausea and vomiting and the like due to radiotherapy chemotherapy for cancers can be effectively relieved.

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol B1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. The compound has good anti-tumor activity to various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells SGC-7901, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC, human gastric carcinoma cells HGC-27 and human lymphoma cells RAJI.

The invention discloses 3-phenylcoumarin robustic acid as well as an extraction method and application thereof. 3-phenylcoumarin robustic acid has a structural formula as shown in the specification as well as a chemical name of 3-(p-methoxyphenyl)-4-hydroxy-5-methoxy-2', 2'-dimethyl-6,7-dihydropyrancoumarin, a molecular formula of C22H20O6, and relative molecular weight of 380. 3-phenylcoumarin robustic acid disclosed by the invention has anti-tumor and other biological activities, can be effectively applied in preparation of anti-tumor drugs and has very strong inhibition effect on human gastric cancer cells, liver cancer cell lines, human lung cancer cells, cervical cancer cells, ovarian cancer cells and the like, the extraction method is simple and feasible and the extraction efficiency is relatively high.

The invention provides a novel immunomodulatory protein FIP-ppl derived from a fungus by applying a genetic engineering means for the first time. According to the invention, a gene which codes the protein is provided and synthesized. The protein FIP-ppl has immunomodulatory and anti-tumor effect. Experiments verify that the protein has a catalytic splitting effect on splenic lymphocyte and can add synthesis of interleukin 2; the protein has remarkable suppress proliferation and apoptosis-inducing effects of the protein on hepatoma carcinoma cell HepG2 and gastric carcinoma cell MCG823 are further verified. The protein FIP-ppl provided by the invention is lowly homological with almost found immunomodulatory proteins of fungi and is a novel immunomodulatory and anti-tumor biological preparation.

A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.

The invention discloses the specificity marker protein TS / MEDP antibody preparation and the purpose. The molecular biology technology is utilized, and a new gene is cloned in a stomach cancer cell and is named as TS / MDEP. A polyclonal antibody for preventing the TS / MDEP is prepared, and a high specificity antibody is acquired through the antibody purification technology. The expression characteristics of the TS / MDEP gene in a tumor cell line and a tumor cell tissue are verified from the mRNA and protein level, the expression in 14 tumor cell lines including the tumor cell line is determined, the dependance of cell cycle is assumed, the excess expression exists in stomach cancer, breast cancer and cervical cancer tissues, no expression is in the corresponding normal tissues, and the expression exists in an embryo tissue. The high expression of the TS / MDEP in the embryo tissue with exuberant cell proliferation is validated, after growing up, the gene is closed, and the high expression exists in the tumor cells. The TS / MDEP has the seasonal specificity expression to clew the occurrence and the development of the cell cycle control abnormity caused by the high expression of the TS / MDEP. The obtained antibody for preventing the TS / MDEP can be used to monitor the cell cycle advancement and the clinical biological behavior of the gastroenteric tumor.

The invention discloses a preparation method of a quercetin amide derivative and application of the quercetin amide derivative in preparing an antitumor drug. The preparation method of the quercetin amide derivative comprises the following steps of: carrying out benzyl selective protection, a Williamson ether forming reaction, a DCC (Dicyclohexylcarbodiimide) condensation reaction, catalytic hydrogenation and the line by using cheap rutin as the material. The preparation method of the quercetin amide derivative can be used for realizing the orientation and efficient modification of the quercetin, and is gentle in reaction conditions, simple to operate, simple in post-treatment and convenient for industrial production. The obtained quercetin amide derivative obviously has a stronger inbibitional effect to proliferation of a human esophageal squamous carcinoma cell EC (Ethyl Cellulose)109, a human esophageal squamous carcinoma cell EC9706, a human gastric carcinoma cell SGC (Soluble Guanylyl Cyclase) 7901 and a mouse melanoma cell B16-f10 relative to the quercetin, and therefore, the quercetin amide derivative is an anti-tumor candidate compound with great potential.

The present invention provides a combination of genes useful for information which can be used for the prediction of postoperative recurrence of gastric cancer and the acquisition of the information, a probe detecting these genes and a primer set for PCR, a method for detecting these genes using the primer and the primer set and a method for obtaining the information which can be used for the prediction of recurrence. Information useful for the prediction of postoperative recurrence can be obtained by determining the presence or absence of gastric cancer cells which show a possibility of postoperative recurrence in a sample such as an peritoneal wash collected from a patient by detecting a particular gene specific to gastric cancer cells or a gene product thereof.

The invention discloses an S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound, a preparation method and application thereof. The compound has a structural general formula shown as formula I. The S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound has an obvious control effect on potato late blight, cucumber fusarium wilt, Botrytis cinerea Pers, Pepper Phytophthora blight, rice sheath blight, wheat scab, Colletotrichum musae, asparagus stem blight and the like, and can be used as an agricultural fungicide in control of plant diseases. At the same time, the compound has an inhibitory effect on HL-60 human leukemia cells, MCF-7 human breast cancer cells, BGC-823 human gastric cancer cells, Bel-7402 human hepatocellular carcinoma cells, and KB human nasopharyngeal carcinoma cells, etc., and has application prospects in the aspect of anti-tumor activity. (formula I).

The invention discloses a purrocoline derivative and a synthetic method and application thereof. The purrocoline derivative with a novel structure can be prepared by reacting propargyl alcohol and a 2-alkyl pyridine compound by taking samarium trifluoromethanesulfonate as a catalyst under the condition without a solvent; the reaction consumption and the chemical contamination are reduced, the cost is reduced and the operation is simplified; the obtained purrocoline derivative has better activity on a gastric cancer cell strain MGC80-3. The structural formula of the purrocoline derivative is shown in a formula (I) in the specification, wherein R<1> is phenyl, 4-methoxyphenyl, 4-fluorophenyl and 2-chlorphenyl or thienyl, R<2> is phenyl, and R<3> is H, phenyl, methyl, a nitrile group or an ethyl acetate group.

The invention discloses a 3-(3,4,5-trimethoxybenzoyl)-benzofuran microtubulin inhibitor as well as a preparation method and use thereof. A 3-(3,4,5-trimethoxybenzoyl)-benzofuran compound in the invention has an action mechanism similar to colchicine and is capable of inhibiting polymerization of microtubulins. The 3-(3,4,5-trimethoxybenzoyl)-benzofuran compound has very strong proliferation inhibition activity to human lung cancer cells A549, human gastric cancer cells MGC-803, human liver cancer cells HepG2, human colon cancer cells HCT-116, human cervical cancer cells HeLa and human breast cancer cells MCF-7.

Methods of treating gastric cancer and reducing the viability of gastric cancer cells by administering folinic acid, fluorouracil, and oxaliplatin to a subject, and applying an alternating electric field to a target region of the subject are provided. In some instances, chemotherapy such as XELOX, FOLFOX and individual components thereof are administered to a subject followed by applying an alternating electric field to the subject.

The invention relates to applications of nicotinamide adenine dinucleotide in the field of pharmacy, and more specifically relates to applications of nicotinamide adenine dinucleotide in preparation of a medicine used for curing liver damages caused by chemotherapy drug doxorubicin hydrochloride. NAD<+> is capable of preventing and treating liver damages caused by chemotherapy drug doxorubicin hydrochloride effectively; and it is also found that NAD<+> is capable of killing glioma cells, neuronal tumor cells, gastric cancer cells, renal tumor cells or breast tumor cells effectively, but possesses no killing effect on normal primary cells.

The invention discloses an anti-human CEACAM5 monoclonal antibody and a preparation method and application thereof, and the anti-human CEACAM5 monoclonal antibody is produced by a mouse hybridoma cellline with the accession number CCTCC NO: C2016129. The preparation method comprises the following steps: S1, immunizing a mouse with whole cell protein, lysed by human gastric cancer cells, as an immunogen; S2, fusing spleen cells of the immunized mouse obtained in the step S1 with mouse myeloma cells; S3, selecting a hybridoma cell line stably secreting antibodies after cell cloning occurs during the cell fusing in the step 2; and S4, preparing the anti-human CEACAM5 monoclonal antibody from the hybridoma cell line stably secreting the antibodies obtained in the step 3. The monoclonal antibody can be used to prepare a composition for treating a malignant tumor. The anti-human CEACAM5 monoclonal antibody can be widely used in various routine operations such as flow cytometry, immunohistochemical staining and immunoprecipitation.

The invention relates to benzimidazole compounds capable of suppressing gastric acid secretion, resisting helicobacter pylori and exerting targeted inhibition of activity gastric cancer cells of the formula on the right. Structurally, the compounds have two benzimidazole active functional groups which can be combined with two cysteine residues in a H<+>, K<+>-adenosine triphosphatase (ATP) monomer or two cysteine residues in an oligomer after being activated by the gastric acid in vivo to inhibit the activity of the H<+>, K<+>-ATP. The compounds can selectively inhibit the activity of Hp. A, B, L, R1 and n are defined in the claim 1.

The invention belongs to the field of genetic engineering and in particular relates to an application of long non-coding RNA (lncRNA) DUXAP8 to prognosis of gastric cancers and target drug treatment. With up-regulation of IncRNA DUXAP8 in gastric cancer cells, prognosis of patients with IncRNA DUXAP8 with high expression level is relatively poor. Effects are exerted on invasion, migration, and the like of the gastric cancer cells by changing expression of IncRNA DUXAP8. Gastric cancer cell proliferation and apoptosis induction can be inhibited by knocking down IncRNA DUXAP8 expression.

The invention provides a periplaneta americana preparation and applications of the periplaneta americana preparation in preparing medicines for treating gastric cancer. Periplaneta americana is treated by adopting an extraction process or an ultralow-temperature grinding process. The research shows that periplaneta americana extract and periplaneta americana medicinal powder can effectively inhibit the expression of VEGF in gastric cancer cells SGC-7901, and have an obvious inhibiting effect for the proliferation of the gastric cancer cells or gastric cancer tumors. The research further shows that after the periplaneta americana extract and the periplaneta americana medicinal powder are respectively mixed with 5-aza-2'-deoxycytidine for use, the inhibition ratios for the proliferation of the gastric cancer cells SGC-7901 cultured in vitro are high, and are respectively 75.1% and 83.9%; after the periplaneta americana extract and the periplaneta americana medicinal powder are mixed with TNP-470 for use, the tumor inhibition rates for the transplantation tumor of tumor-bearing mice are respectively 75.3% and 86.5%.

The present invention provides the use of a long-chain non-coding RNA lncRNA-RP11-290F20.3 in the preparation of a kit for diagnosis and / or prognosis evaluation of gastric cancer, and the small interference of the lncRNA-RP11-290F20.3 Use of RNA in the preparation of medicines for preventing or treating gastric cancer. The lncRNA-RP11-290F20.3 of the present invention is highly expressed in human gastric cancer tissues and gastric cancer cell lines, and the small interfering RNA of lncRNA-RP11-290F20.3 has the function of inhibiting the proliferation, invasion and migration of gastric cancer cells. Therefore, the lncRNA The small interfering RNA of ‑RP11‑290F20.3 can be used as a new type of drug target, which is of great clinical significance for the prevention and treatment of gastric cancer.